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Background: Natural medicinal products have gained recognition worldwide in the treatment and control of
diseases. One of the major concerns as they are used is the lack of adequate pharmacological and toxicological
data to support their use. Myrsine africana is traditionally used as human and veterinary anthelmintic.
Methods: Two groups of male Wistar rats were orally given as a single dose 1000 and 5000 mg/kg body weight of
the M. africana extract respectively. Hematological and biochemical assays of each animal blood were done after
48 h and at day 14.
Results: No animal died in the entire study period. The median lethal dose (LD50) of the seed extract was
estimated to be above 5000 mg/kg body weight in Wistar rats. Red blood cells, packed cell volume and creatinine
in rats fed with 5000 mg/kg body weight were found to be significantly elevated from the control at 48 h. At day
14, thrombocytes and aspartate aminotransferase were significantly elevated in the high dose group while urea
level had decreased significantly in the treatment groups.
Conclusions: M. africana extract was found to have a high safe margin validating its wide use. However, caution
should be exercised when using this extract as was indicated by the altered parameters. It is therefore recommended
that lower doses than 1000 mg/kg body weight should be used for treatment.
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Since antiquity, man has used plants to treat common
diseases even long before mankind discovered the exist-
ence of microbes. An 80 % of the population in the non-
developed countries depends on traditional medicine for
their primary health care [1]. According to International
Development Research Centre (IDRC), 85 % of Africans
use herbal remedies in their routine health care in
Sub-Sahara Africa [2]. Natural products remedies are
esteemed safer and less damaging to the human body
than the synthetic drugs [3]. The safety of herbal medi-
cine has continually been questioned due to reported* Correspondence: zelipha.kabubii@uonbi.ac.ke
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Toxicological studies are important in hazard identifica-
tion stage of safety assessment of drugs. Regulatory safety
assessment for natural products relies on both the assess-
ment of cases of adverse reactions and the review of pub-
lished toxicity information effects [5]. Earliest report of
the toxicity of herbs originated from Galen, a Greek
pharmacist and physician. He showed that herbs do not
contain only therapeutic constituents, but that they may
also contain harmful substances [6]. Acute toxicity is a
term used to describe the adverse effects that are caused
by a single exposure of a toxic substance or brief multiple
exposures over a very short span of time –usually less
than 24 h. The described acute toxicity should occur
within 14 days of administration of the substance [7].le is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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median lethal dose (LD50) of a substance [8].
Myrsine africana also called Cape Myrtle or African
boxwood is a Myrinaceae and is an evergreen shrub
growing to 2 m at a slow rate. The plant native to Africa
and Asia and usually grows well in dry parts. Myrsine
africana typically has dense, dark-green to red foliage
and produces tiny bright purple berries which are
edible. The seeds and roots of M. africana are widely
used for livestock and human as an anthelmintic, es-
pecially in the treatment of tapeworms [9, 10]. This
plant is also used for the treatment of diarrhea,
rheumatism, toothache pulmonary tuberculosis and
relieving hemorrhage [11]. M. africana is traditionally
used as a fragrance in tea, carminative, spice, appetizer
and flavoring agent [12]. There are no published con-
ventional safety studies on Myrsine africana despite
widespread use as an anthelmintic [12–14]. This study
was therefore projected to evaluate this plant acute
toxicity effect on the hematological and biochemical
parameters in order to validate its use.
Methods
M. africana seeds were collected from the Samburu area
of Kenya. Identification and authentication was done at
the herbarium, School of Biological Sciences, University
of Nairobi.
Extraction of seeds materials
The M. africana seeds were cleaned in tap water and
rinsed in distilled water. After air-drying at room
temperature (22-26 °C) to a constant weight, the seeds
were ground to a uniform powder using an electric mill.
The powder (100 g) was soaked in 1 L distilled water for
48 h. The mixtures was filtered through cotton wool and
then with filter paper (125 mm) after which the filtrate
was frozen at -20 °C for 24 h followed by freeze drying.
The powdered extract was packed and sealed in air tight
polythene bags, stored in the refrigerator at 4 °C and
used within five days.
Laboratory animals
A total of 15 male Wistar albino rats (195 – 225 g) were
obtained from the animal house of the department of
Biochemistry, University of Nairobi. The animals were
housed in the research room of this department and the
temperatures were maintained at 27– 30 °C. The room
was well ventilated and maintained on light for 12 hours
and 12 h darkness. The rats were provided with the
standard rat pellets and clean water ad libitum. The ani-
mal studies were in compliance with the ethical proced-
ure for the care and use of laboratory animals approved
by the “Animal care and use committee (ACUC)” of the
Faculty of Veterinary Medicine University of Nairobi.Experimental design for acute toxicity
The animals were randomly assigned into three groups
of five rats each. They were kept overnight fasting prior
to extract administration. Group 1 served as the control
and the rats were administered with 2 ml distilled water
once. Two concentrations of the aqueous extract, 1000
and 5000 mg/kg body weight were constituted each in
2 ml distilled water respectively. These extracts were or-
ally given as a single dose and only once to groups 2 and
3 respectively using a gavage. Food was withheld for fur-
ther 3 h post extract administration.
Animal bleeding, hematological and biochemical assays
Blood was collected at from each rat at 48 h and the
14th day post extract administration via the tail lateral
vein using a 2 ml hypodermic syringe and needle when
the animal was restrained. A blood aliquot (1.3 ml) was
put into the EDTA tubes and thoroughly mixed for
hematological analysis. The remaining 0.5 ml of the
blood was put in the plain tube for biochemical analysis.
Hemoglobin concentration (HB), packed cell volume
(PCV), red blood cells (RBC), white blood cells (WBC),
mean corpuscular hemoglobin (MCH), mean cell vol-
ume (MCV), mean corpuscular hemoglobin concentra-
tion (MCHC) and thrombocytes were analysed within
six hours using “Melet Schoesing MS4” hematological
analyzer. The blood in the plain tubes was immediately
centrifuged at 3000 revolutions per minute for 10 min to
extract serum which was stored at −20 °C and used
within 12 h for biochemical assays. Aspartate amino-
transferase (AST), alanine aminotransferase (ALAT),
total proteins, creatinine, urea were assayed for each rat
using commercial kits according to the manufacturer’s
protocol using “UVmini-1240 UV–vis” spectrophotom-
eter manufactured by “Shimadzu”.
Physical observation
Clinical observations were made after every 30 min post
extract administration for the first four hours and latter
once a day up to the 14th day. Mortality, moribund, ill
health or reaction to treatment, such as changes in skin
and fur, eyes and mucus membranes, behavior pattern,
tremors, salivation, diarrhea, sleep and coma were ob-
served. Weight recording was done before extract ad-
ministration, at 48 h, day 7 and day 14.
Statistical analysis
The analysis was done using SPSS 17.0 and the results
were expressed as mean ± standard deviation of the
mean (SD). One-way analysis of variance (ANOVA) was
employed for between and within group comparison.
95 % level of significance (p ≤ 0.05) was used for the stat-
istical analysis.
Table 2 Effect of M.africana on hematological and biochemical
measurements in male Wistar rats at 48 h
Parameter Control 1000 mg/ 5000 mg
WBC (103/μL) 10.1 ± 2.7 10.9 ± 5.3 8.1 ± 1.5
RBC (106xμL) 5.6 ± .22 6.1 ± 1.3 *7.6 ± 9.8
PCV (%) 35.1 ± 1.5 34.3 ± 8.1 *44.1 ± 5.3
Hb (g/dL) 14.0 ± .81 13.9 ± 2.5 14.5 ± .32
MCV(fL) 63.9 ± .60 57 ± 2.7 59.7 ± 1.2
MCH(pg) 24.0 ± 1.2 24.3 ± 1.2 22.3 ± 3.0
MCHC (g/dL) 38.5 ± .91 43.5 ± 3.2 32.4 ± 5.3
THROMB (103/μL) 336.2 ± 59.8 441 ± 99 419 ± 8.9
AST (U/L) 45.6 ± 15.1 41. 6 ± 7.3 38.1 ± 12.0
ALAT(U/L) 46.4 ± 2.4 42.1 ± 4.9 44.6 ± 4.2
Total proteins (g/dL) 7.7 ± 5.2 7.5 ± .86 8.2 ± .9
Creatinine (mg/dL) 1.7 ± .36 4.2 ± 4.5 *15.6 ± 2.1
Urea (mg/dL) 42.9 ± 3.7 46.8 ± 3.8 46.8 ± 8.0
*Significantly different
Table 3 Effect of M.africana on hematological and biochemical
measurements in male Wistar rats at day14
Parameter Control 1000 mg/kg/bwt 5000 mg/kg bwt
WBC (103/μL) 9.1 ± .34 12.27 ± 1.4 18 ± 3.1
RBC (106xμL) 5.7 ± .57 6.37 ± .31 6.3 ±. 62
PCV (%) 35.2 ± 3.1 38.9 ± 1.7 37.3 ± 2.6
Hb(g/dL) 12.8 ± 1.5 15.2 ± .94 15.2 ±. 71
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In this study, the rats in the control and treated groups
were monitored daily until day fourteen and they showed
no toxic signs. This study suggested that M. africana
aqueous extract has an LD50 > 5000 mg/kg body weight in
albino Wistar rats since none of the experimental animals
died within the 14 days study period. According to [15]
substances with LD50 values less than 5000 mg/kg body
weight are classified as substances with low toxicity. The
weight change of the treated animals was not significantly
different from the control, Table 1, validating the low tox-
icity of this extract. It was suggested that this extract did
not cause any inflammation in the animals. This was
reflected by the non-significant increase in the white
blood cells, Tables 2 and 3. White blood cells are usully in-
creased when the immune system is triggered thus offer-
ing protection to the body from infection by foreign
organisms [16]. Red blood cells (RBC) and packed cells
volume (PCV) at 48 h in 5000 mg treatment group were
significantly elevated and both normalized at day 14,
Tables 2 and 3, suggesting that there may have beeen a
correlation between these responses and dosage [17]. An
increased RBC and unaltered WBC suggestes a strong
immuno-modulatory activity of Myrsine africana extracts
[18]. Hemoglobin concentration (HB), Mean cell volume
MCV), mean corpuscular hemoglobin (MCH) and mean
corpuscular hemoglobin concentration (MCHC) at 1000
and 5000 mg/kg body weight did not have significant dif-
ferences with the control suggesting that Myrsine africana
at these doses did not induce anaemia in the rats. This is a
mark of high safety margin of the extract through oral
route justifying its widespread use by traditional healers in
Kenya [19]. Thrombocytes (platelets) in the treated groups
increased, Tables 2 and 3 both at 48 h and at day 14
strongly suggest that there could be some bioactive com-
pounds in Myrsine africana seeds that can enhance
thrombopoiesis [20].
Acute toxicity is usually defined as the adverse
change(s) occurring immediately or a short time follow-
ing a single or short period of exposure to a substance
or substances [21]. The assessment of hematological pa-
rameters could be used to reveal the deleterious effect ofTable 1 Weight profile for the male Wistar rats in M.africana
acute toxicity testing
Time Control 1000 mg 5000 mg
Initial weight 217.4 ± 9.4 222.4 ± 5.8 224.9 ± 5.6
At 48 h 219.2 ± 8.9 219.1 ± 8.0 222.7 ± 7.0
7 days 226.9 ± 8.7 226.9 ± 7.6 232.9 ± 6.6
14 days 239.2 ± 8.6 243.2 ± 10.4 246.6 ± 10.5
Total gain 22.0 ± 1.5 20.8 ± 5.4 21.7 ± 7.5
% weight gain 8.5 7.9 8.2foreign compounds including herbal extracts on the
blood constituents of animals. They are also used to de-
termine possible alterations in the levels of biomolecules
such as enzymes, metabolic products, and the normal
functioning of the organs [22].
The liver plays a major role in the metabolism and de-
toxification of compounds that reach the liver and hence
the prime target organ for drugs and toxic substances
[23]. The significantly elevated AST at the 14th days in
both treatment groups, and not at 48 h is an indication
of cellular damage [24]. ALAT is more specific to the
liver and thus a better parameter for detecting liver in-
jury [25]. In this study there was no significant difference
of ALAT of the treated groups with the control groupMCV(fL) 63 ± 1.4 59.9 ± .78 60.1 ± 4.0
MCH(pg.) 23.8±. 82 23.2 ± .61 22.4 ± 4.7
MCHC (g/dL) 38 ± 1.1 39.4 ± 1.2 39 ± 1.4
Thromb. (103/μL) 186 ± 20 288 ± 44.7 *564 ± 71
AST (U/L) 34.46 ± 7.5 *57.2 ± 5.9 *55.4 ± 4.1
ALAT(U/L) 44.7 ± 6.4 45 ± 4.6 48.1 ± 5.9
Total proteins(g/dL) 8.7 ± 2.2 6.5 ± .76 8.7 ± 1.8
Creatinine (mg/dL 1.8 ± 1.3 1.9 ± .78 1.9 ± .22
Urea (mg/dL) 42.8 ± 6.2 *21.8 ± 5.0 *27.8 ± 4.7
*Significantly different
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ously cause liver toxicity. Creatinine level was signifi-
cantly elevated at a dose of 5000 mg/kg body weight at
48 h but not at day14, an indication that the extract was
effectively eliminated by the kidneys [26]. A biologically
active components capable of reducing urea content in
the animals could have been present in the extract as it
was indicated by the low urea values in day 14. Ineffi-
cient absorption of proteins, tubular necrosis and liver
diseases are among the factors that can cause reduced
serum urea [27].
Conclusions
Caution should be exercised when using this natural prod-
uct extract as was indicated by the altered biochemical pa-
rameters; AST, urea and creatinine. It was recommended
that lower doses than the studied ones should be used for
treatment. Further studies to evaluate sub-acute and
chronic effect of this extract are recommended.
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